![]() |
Ceftriaxone Induced Hemolytic Anemia...
November 1, 2013 - Clinical , Featured By: Samad Tirmizi, PharmD Candidate c/o 2014 – Hemolytic anemia (HA) is a type of anemia that occurs due to the breakdown of red blood cells. It is classified as intrinsic and extrinsic according to causative factors. Medication induced hemolytic anemia is an example of extrinsic, while genetic predisposition is an intrinsic factor. Drug induced… |
![]() |
Does Moxifloxacin Increase the Risk of Dysglycemia?...
November 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2014, AMSCOP at LIU – The antibiotic class known as the fluoroquinolones is widely used in both outpatient and inpatient settings. They provide bactericidal effects by inhibiting DNA gyrase and topoisomerase IV enzymes in bacteria. The systemic agents that are most commonly used in clinical practice include ciprofloxacin, levofloxacin,… |
![]() |
What You Should Know About Selecting APPE Rotations...
October 1, 2013 - Professional Advice / Opinions By: Aleena Cherian, Co-Copy Editor, Graphics Focused – Selecting APPE Rotations You’ve made it past the progression interviews at the end of 2nd year, the White Coat Ceremony, and the mind-boggling compounding and kinetics equations. You’re almost done with those labs and late night D&D study sessions. Now, halfway through the first semester of your… |
![]() |
After 15 Years, First New Recombinant Coagulation Facto...
October 1, 2013 - Clinical By: Tamara Yunusova, Senior Staff Editor – After a lengthy fifteen-year hiatus in recombinant drug approvals, FDA-approved Recombinant Coagulation Factor IX (Rixubis) has mounted to the forefront of Hemophilia B drug therapy. The recombinant coagulation factor gained orphan drug approval on June 26, 2013 for routine prophylaxis, control of bleeding episodes, and perioperative management in… |
![]() |
Hope For Children with Acute Lymphoblastic Leukemia...
October 1, 2013 - Featured , In the News / Politics By: Ada Seldin, Staff Editor – Emily Whitehead, a 7-year-old girl who fought off relapsing acute lymphoblastic leukemia (ALL), has captured the hearts and prayers of the masses. Her story is an inspiration to those battling any disease with a poor prognosis and particularly holds promise for the 15% of children with ALL resistant to… |
![]() |
Meet the Dean: Interview with Dean DiGate...
October 1, 2013 - Featured , Professional Advice / Opinions By: Katharine Cimmino, Editor-in-Chief and Erica Dimitropoulos, Senior Staff Editor – Just last month, St. John’s University College of Pharmacy and Health Sciences kindly welcomed a new Dean into our family, Dean Russell J. DiGate. Dean DiGate is a highly experienced educator and academic leader. He attended the University of Rochester, where… |
![]() |
Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are… |
![]() |
A Close Concurrence on Certolizumab (Cimzia®)...
September 1, 2013 - Clinical , Featured By: Sang Hyo Kim, Staff Editor – This year, on July 23rd, FDA advisers voted 7 to 6, with one abstention, in favor of approving the drug certolizumab (Cimzia®) for the indication of axial spondyloarthritis (axSpA). axSpA is a chronic imflammatory condition that includes ankylosing spondylitis (AS) and non-radiographic axial spndyloarthristis (nr-axSpA).1,2 axSpA, AS and… |
![]() |
New Findings Regarding Cardiovascular Adverse Events wi...
August 1, 2013 - Clinical , Featured By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve… |
![]() |
Drugs and Diseases: The Survival Manual...
August 1, 2013 - Professional Advice / Opinions By: Beatrisa Popovitz, Staff Editor – You may have heard the countless horror stories passed on by upperclassman of how D&Ds seep into the crevices of our brains and take over our psyches to inevitably make us breathe, sleep, and speak pharmacy. Stressing out over exams and investing what may seem like all of your… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
Solving the HCV Enigma: Current and Future Drug Therapy...
July 1, 2013 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are not common, rates of chronic hepatitis C continue to surge due to the recent discovery of the virus in 1989 and consequently, the establishment of a test screening for HCV antibodies in 1992.1 HCV has… |
![]() |
Journey to a PharmD...
July 1, 2013 - Professional Advice / Opinions By: Jacqueline Chirico; Pharm D Candidate c/o 2016 – The reasons behind the choice to study pharmacy here at St. John’s University vary from student to student. Some are interested in helping patients, while others are interested in the science behind how drugs affect the body. For me, it was the experience that I had… |
![]() |
Angelina Jolie’s Double Mastectomy: What it Reveals A...
July 1, 2013 - Professional Advice / Opinions By Sang Hyo Kim, Staff Editor – Angelina Jolie, the actress recognized for her charismatic beauty, revealed to the New York Times that she had undergone double mastectomy, the surgical removal of the breasts. Because her mother died of ovarian cancer at 56, when Jolie learned that she had a mutation in her BRCA1 gene,… |
![]() |
Faculty Spotlight: Dr. Heather Mavronicolas Forges the ...
July 1, 2013 - Featured , Professional Advice / Opinions By: Tasnima Nabi, Content-focused Co-Copy Editor – The College of Pharmacy and Health Sciences has officially launched a Master of Public Health (MPH) degree program and accepted applications for Fall 2013. Public Health has become an increasingly important area of study over the years as our country experiences rising numbers of chronic disease, health care… |
![]() |
FDA Approves Dimethyl Fumarate for Treatment of Relapsi...
June 1, 2013 - Clinical , Featured By: Andy Zhang, PharmD Candidate c/o 2015 – On March 28, 2013, the U.S. Food and Drug Administration announced the approval of Tecfidera™ (dimethyl fumarate) for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 Tecfidera™ (dimethyl fumarate) will be the third oral drug used for the treatment of MS. The manufacturer Biogen… |
![]() |
Noninvasive Cancer Screening—Will We Ever Get It Righ...
June 1, 2013 - Clinical , Featured By: Frances Sousonis, Candidate c/o 2017 – Unfortunately, cancer is a disease about which many are able to share stories. All too often, beloved persons are diagnosed with cancer, or, more regrettably, loses their battle with the beast. Colon cancer is the third most common cancer in the United States and around 150,000 people each… |
![]() |
Disclosure of Clinical Research Funding: Can Ignorance ...
May 1, 2013 - Professional Advice / Opinions By: Bharat Kirthivasan, Co-Copy Editor [Content-Focused] – Most people would prefer that a research paper be mandated to disclose its source of funds. For example, if a publication effusively supports a certain drug, we want to know if its parent company is footing the bill. Transparency allows research to be viewed in light of its… |
![]() |
Regulation of Low to Moderate Risk Medical Devices by t...
May 1, 2013 - Featured , Professional Advice / Opinions By: Hayeon Na, Co-Copy Editor [Content-Focused] – On March 22, 2013, Public Broadcasting Service (PBS) aired an episode of “Need to Know” on the safety of low to moderate risk medical devices. The episode closely followed the lawsuit of patient Linda Gross who has pelvic organ prolapse and was advised by her doctor to undergo… |
![]() |
College of Pharmacy and Health Sciences Hosts Year-End ...
May 1, 2013 - Events By: Tasnima Nabi, Senior Staff Editor – On May 2nd, St. John’s University College of Pharmacy and Health Sciences hosted the “Pre-Finals Relax, Refresh, Recharge Luncheon” on the Great Lawn. The event took place from 12:00 pm till 3:00 pm, with an array of activities. Students were able to picnic on the Great Lawn with… |
![]() |
AUVI-Q™: The Newest Epinephrine Device to Hit the Mar...
May 1, 2013 - In the News / Politics By: Diana Gritsenko, Pharm D. Candidate c/o 2015 – Most of us who work in a community pharmacy setting will usually get a few scripts a month for an Epi-pen™. An Epi-pen™ is a device that autoinjects epinephrine (also known as adrenaline) into a patient who is experiencing anaphylaxis. Anaphylaxis is a severe, whole-body allergic… |
![]() |
Plan B® Pill Now Available Without Prescription to Wom...
May 1, 2013 - Featured , In the News / Politics By: Bansri Patel – As of May 1st 2013, Plan B®, the brand name emergency contraception pill will now be available to women aged fifteen and older. It will also be sold in the drug store aisles, as opposed to its current location behind the pharmacy counter. When levonorgestrel (Plan B®) first entered the market,… |
![]() |
The Honors Program Spotlight...
April 1, 2013 - Events By: Steve Soman – The St. John’s University Honors Program features small classes, faculty mentoring, and an impressive number of academic and cultural opportunities for students to excel. These opportunities range from performances at the Metropolitan Opera, New York City Ballet, and the New York Philharmonic to museum visits and Manhattan walking tours. For students… |
![]() |
FDA Approves New Drug ‘Tofacitinib’ for Rheumatoid ...
April 1, 2013 - Clinical , Featured By: Erica Dimitropoulos, Senior Staff Editor – Rheumatoid arthritis is a painful and often debilitating autoimmune disease characterized by symmetric polyarthritis, most commonly of the proximal interphalangeal and metacarpophalangeal joints, elbows, knees, ankles, and spine.1 Its clinical manifestations vary, from a slowly progressing onset of fatigue and musculoskeletal discomfort to a sudden and worsening destruction… |
![]() |
Merck Settles Lawsuits Over Vytorin...
April 1, 2013 - In the News / Politics By: Tasnima Nabi, Staff Editor – Merck & Co. will pay $688 million to settle two lawsuits filed in December 2008 over their patent-protected statin, Vytorin®. The suits state that Merck and Schering-Plough delayed releasing the results of their ENHANCE study to avoid a decrease in revenue.1 Vytorin® is a combination drug of simvastatin and… |
![]() |
Increased Costs of Treatment due to the DSM-V: Implicat...
April 1, 2013 - Featured , In the News / Politics By: James W. Schurr and David Gao, PharmD Candidates 2014 – A recent Op-ed in Newsday by Allen Frances, MD (of Duke University School of Medicine and chairman of the task force that produced the DSM-IV, the current guidelines for psychiatric disease diagnosis) criticizes the American Psychiatric Association for being “extravagantly indifferent to all matters… |
![]() |
Documentation of Drug Allergies in Hospitalized Older A...
April 1, 2013 - Clinical , Featured By: Nandini Puranprashad, PharmD Candidate; Sibyl Cherian, PharmD Candidate; Tracey Cannova, PharmD Candidate; and Olga HilasPharmD, MPH, BCPS, CGP – Adverse drug reactions are estimated to occur in 10-20% of hospitalized patients and in 7% of the general population.1 One-third of these reactions are of an allergic or pseudo-allergic nature. The consequences of these hypersensitivity… |
![]() |
New P2Y12 Antagonist on the Rise...
April 1, 2013 - Clinical By Nancy Rizkalla, PharmD candidate c/o 2015 – Percutaneous coronary intervention (PCI) with subsequent stent implantation is a highly effective approach in reducing the risk of death or ischemic complications following a myocardial infarction as well as improving the quality of life in patients with stable angina. PCI is ultimately performed in 60 –… |
![]() |
New FDA Approval: Fycompa® to Treat Seizures...
March 1, 2013 - Clinical , Featured By: Bhavini Shah, PharmD Candidate c/o 2013 – Fycompa® (perampanel) has received the U.S. Food and Drug Administration (FDA) approval for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.1 The drug, manufactured by Eisai Inc., is already approved for use in Iceland,… |
![]() |
FDA Approves New Indication for Botox (Onabotulinumtoxi...
March 1, 2013 - Clinical , Featured By: Bethsy Jacob, PharmD Candidate 2014 – On January 18, 2013, the U.S. Food and Drug Administration (FDA) announced a new approval for Botox, generically known as OnabotulinumtoxinA. Patients diagnosed with urinary incontinence due to an overactive bladder can be prescribed Botox, if they are unable to take or are unresponsive to anticholinergic medications. This… |
![]() |
Extending the Standing Order for Tdap...
February 1, 2013 - Featured , In the News / Politics By: Christina Tarantola, PharmD, PGY-1 Resident at Kings Pharmacy – The New York State Department of Health issued a health advisory on November 8, 2012 in response to Hurricane Sandy. The document outlined guidelines on recommended immunizations and disaster relief efforts for volunteers and the general public. Due to an increased risk of exposure to… |
![]() |
A Look at Primary Medication NonAdherence and How it ca...
February 1, 2013 - Featured , In the News / Politics By: Erica Dimitropoulos, Assistant Student Editor – Although clinical trials can affirm the efficacy and advantages of all marketed medications, it is obvious that patients cannot benefit from a drug that they choose not to take. Therefore, promoting medication adherence is one of the easiest and most affordable ways to improve treatment outcomes. In order… |
![]() |
Calcium Intake and Risk of Myocardial Infarction...
February 1, 2013 - Clinical , Featured By: Lila Ahmed, PharmD Candidate c/o 2013 – In the past, numerous research efforts have attempted to prove the benefits and risks of calcium and multivitamin supplements with little success. Most of the studies performed were inconclusive and did not provide us with significant data; while some studies have found that calcium is beneficial for… |
![]() |
Liraglutide (Victoza®) for Type 2 Diabetes Mellitus...
February 1, 2013 - Clinical , Featured By: Miriam Maltz, PharmD Candidate c/o 2013, AMSCOP, Long Island University – Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia that is pursuant to insulin resistance, defects in insulin secretion, or both1. Chronic hyperglycemia is associated with detrimental effects on various organ systems that can increase mortality and impact the patient’s… |
![]() |
Emerging Pathways For Treating Hepatitis C Virus...
February 1, 2013 - Clinical , Featured By: Maria Sorbera, PharmD Candidate c/o 2013, AMSCOP, LIU – Hepatitis C is the leading cause of chronic liver disease and cirrhosis, presenting a global health challenge. Approximately 170 million people worldwide, 3% of the population, are infected with the Hepatitis C Virus (HCV), roughly 3.2 million of whom reside in the United States. The… |
![]() |
The Opioid Debate: PROP and PROMPT Battle Away...
January 1, 2013 - Featured , In the News / Politics By: Tamara Yunusova – On Wednesday, July 25th a petition signed by the reform group Physicians for Responsible Opioid Prescribing (PROP) called on the FDA to implement opioid label changes that would restrict Chronic Non-Cancer (CNCP) opioid treatment for patients with severe pain only. It wasn’t too long before another petition signed by PROP’s adversary,… |
![]() |
FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1 This occurred one month after its approval in Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is… |
![]() |
Breakthroughs in Gene Therapy: Pharmacogenetics and Vec...
December 1, 2012 - Clinical , Featured By: Tamara Yunusova, PharmD Candidate c/o 2017 – Gene therapy? You scoff in disbelief as thoughts of designer babies, liberal eugenics, clones, and ruthless dystopian societies begin to reel in the back of your mind. Perhaps you may even stop to recall a scene or two from Jurassic Park or Star Trek. Undoubtedly, gene therapy… |
![]() |
Safety and Efficacy of Atropine for Salivary Hypersecre...
November 1, 2012 - Clinical By: Elsa Thomas, PharmD Candidate c/o 2013 – Atropine is an anticholinergic used to treat various conditions, such as bradycardia, neuromuscular blockade, mydriasis, nerve agent poisoning, and salivary hypersecretion.1,2 Pharmacologically, it inhibits smooth muscle and glands innervated by postganglionic cholinergic nerves.1,2 It also has functions in the central nervous system (CNS); it could stimulate or… |
![]() |
New Drug Review: Tofacitinib (Xeljanz®)...
November 1, 2012 - Clinical By: Jessica Lee, PharmD Candidate c/o 2013 – Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks healthy tissue, causing inflammation of the joints and potential harm to other organs.1 It affects 0.5-1% of the adult population and is more prevalent in the seventh decade of life.1 These patients tend to… |
![]() |
Ivacaftor (KalydecoTM): Targeting the Core of Cystic Fi...
November 1, 2012 - Clinical , Featured By: Eugene Kolomiyets, PharmD Candidate c/o 2013, AMSCOP at LIU – Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7.1 The disease has been linked to thousands of possible mutations, but only as many as 25-30 are tested for… |
![]() |
Low-dose SSRIs for the Overly Sensitive Esophagus...
November 1, 2012 - Clinical , Featured By Sunhae Chang, PharmD Candidate c/o 2013 – When patients complain of heartburn, the blame usually shifts to gastroesophageal reflux disease (GERD). Therefore, patients receive the “standard therapies for GERD”: antacids, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), or prokinetics.1,2 Luckily, most patients respond well to these agents.1,2 Unfortunately, the not-as-lucky ones, despite PPI… |
![]() |
Duloxetine’s Effect on Blood Glucose Levels...
October 1, 2012 - Clinical , Featured By: Neal Shah, Co-Editor-in-Chief – Duloxetine is a serotonin (5HT) and norepinephrine (NE) reuptake inhibitor (SNRI) introduced to the US market in 2004, indicated for the treatment of diabetic neuropathic pain.1 A chemical figure of duloxetine is shown [in the PDF].2 It was developed in an effort to mimic tricyclic antidepressant mitigation of neuropathic pain… |
![]() |
The Role of NMDA in Electroconvulsive Therapy and Other...
October 1, 2012 - Clinical , Featured By: Neal Shah, Co-Editor-in-Chief – Electroconvulsive therapy (ECT) is a last-line procedure in the treatment of refractory depression, among other neuropsychological disorders.1 By inducing a seizure, neurotransmitters are released and the disease state may feature a modest mitigation in symptoms.1 Seizure medications such as benzodiazepines and barbiturates are prescribed to increase or heighten the seizure… |
![]() |
Medications Causing Body Temperature Fluctuations...
October 1, 2012 - Clinical , Featured By: Elsa Thomas, Pharm.D. c/o 2013 – Human body uses various complex mechanisms to maintain its body temperature within a narrow range despite extreme environmental temperature changes as well as physiological changes. Several factors can affect body temperature such as disease states, growth, exercise, hormonal changes, and medications. Hypothermia can occurs as a result of… |
![]() |
Studying Abroad: The Perspective From a Pharmacy Studen...
October 1, 2012 - Professional Advice / Opinions By: Shannon Tellier – When applying to St. John’s University College of Pharmacy and Health Sciences five years ago, I never would have dreamed that I would have the opportunity to study abroad twice while obtaining my PharmD degree. At the end of my freshmen year, there were rumors about second year pharmacy students having… |
![]() |
Influenza Vaccines: Projected Strains for the 2012—20...
September 1, 2012 - Clinical , Featured By: Joo Hee Kwon, Pharm.D. Candidate c/o 2013 – There are 3 antigenic types of influenza: A, B, and C. Influenza C causes mild illness and therefore does not cause epidemics. In contrast, influenza A and B are capable of causing mild to severe flu and in some cases death. An epidemic can occur depending… |
![]() |
Bisphosphonates and Atypical Fracture Risk...
September 1, 2012 - Clinical , Featured By: Steve Soman, Pharm.D. Candidate c/o 2013 – Bisphosphonates are proven to enhance bone density and reduce fracture incidence in post-menopausal women but recent data suggests they may have adverse effects with regards to bone quality. The drugs in this class can be differentiated as non-nitrogen containing (older generation) and nitrogen containing (newer generation) medications.… |
![]() |
Antiplatelet Use Following Acute Coronary Syndromes...
September 1, 2012 - Clinical , Featured By: Addolorata Ciccone, Co-Copy Editor – Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction of coronary arteries. ACS is stratified into three types, based on electrocardiogram (EKG) changes and the presence of cardiac biomarkers (e.g. troponin, creatinine phosphokinase, and myoglobin). To guide treatment plans, it is important to identify… |
![]() |
New Student Convocation Address...
September 1, 2012 - Professional Advice / Opinions By: Mohamed Dungersi, Associate Student Editor – The following address was delivered by one of our student editors on behalf of the students at the College of Pharmacy and Health Sciences as a welcome to St. John’s University to students of the classes of 2016 and 2018. Dean Zito, Administrators, Faculty Members, and students of… |